A coronary sinus reducer met one of two primary endpoints by reducing refractory angina in the ORBITA-COSMIC trial, but not the second, improvement in perfusion.
Neovasc (TSE:NVCN) Shares Up 0 6% kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.